Top of this page
Skip navigation, go straight to the content
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
So let’s disconnect from all screens & enjoy the simple things such as a nice chat with your beloved ones around a cup of coffee or tea (in the morning) or a glass of your favorite drink (in the evening).
Stay well and safe – lots of joy and good health!
Antje, Isabelle & Nathalie
The UCB IR Team
Date | Event details |
---|---|
11 January 2021 | 39th Annual J.P. Morgan Virtual Healthcare ConferenceUCB will participate from 11-14 January 2021 |
25 February 2021 | 2020 full year resultsDetails closer to the date |
Date | Event details |
---|---|
25 February 2021 | 2020 full year results Details closer to the date |
29 July 2021 | 2021 half-year resultsDetails closer to the date |
Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges
reflecting the high R&D investment level, including the investment for the Ra Pharma pipeline
based on an average of 187 million shares outstanding
investor-relations@ucb.com or a specific team member: